COVID-19 Protection: Study Shows That Measles-Mumps-Rubella (MMR) II Vaccine Could Protect Against COVID-19

COVID-19 Protection: Researchers from largest private hospital group in Mexico-Hospital Médica Sur have in a new study found that measles-mumps-rubella MMR II vaccine could offer protection against the COVID-19 disease.


 
The study findings were published in the peer reviewed journal: Allergy (The European Journal Of Allergy and Clinical Immunology) https://onlinelibrary.wiley.com/doi/10.1111/all.14584
 
The current COVID-19 pandemic is accelerating at an exponential phase with daily global infections now crossing the 620,000 mark each day and daily deaths crossing more than 11,000 per day despite stupid media coverage in America and Europe saying that the second wave is peaking or claims that the COVID-19 vaccines are going to provide a solution and that their stupid governments have everything in control!
 
The number of reported global SARS-CoV-2 infections today stands at 58.02 million as and this number continue to rise despite restrictions or lockdowns. A total of 1.38 million have died from COVI9-19 with another half a million more expected to die within the next 40 days till the New Year. Sadly a bulk will be in America and Europe; countries famed for their arrogance and know it all mentality.
 
Ironically their own health systems have not been readily equipped to tackle the growing impact of the second wave and already their public healthcare systems are overstretched. Forget about the long term effects and medical conditions arising from Long COVID as their healthcare systems cannot even afford to do proper follow up screenings etc.
 
A research published this month in mBio, a journal of the American Society for Microbiology, has produced evidence that supports earlier theories that an existing vaccination may protect against the more severe symptoms of SARS-CoV-2 infection. https://mbio.asm.org/content/11/3/e00907-20
 
https://mbio.asm.org/content/11/6/e02628-20
 
The research team found an inverse correlation between levels of mumps titers and the severity of COVID-19 disease symptoms in those who had been vaccinated with the measles-mumps-rubella MMR II vaccine.
 
In early September, a research team at Medica Sur in Mexico City, led by Dr Larenas-Linnemann, published the findings of their latest study, which suggested the role of the MMR vaccine in reducing symptom severity of COVID-19.
 
In this paper, the researchers explained how individuals vaccinated with the MMR vaccine since the beginning of the pandemic seemed to develop less severe symptoms than would be expected.
 
To follow up on the earlier hypothesis, the study team set up a study to investigate the possible connection between the MMR vaccine and COVID-19 symptom severity.
 
For the study, 80 individuals were recruited and allocated into one of two groups, an MMR II group consisting of 50 subjects who primarily had MMR antibodies from the MMR II vaccine, and a comparison group, consisting of those with no record of MMR II vaccinations, and who would have obtained any MMR antibodies from other sources such as prior infections with measles, mumps, or rubella.
 
The research findings showed that mumps titers and the severity of COVID-19 symptoms were significantly inversely correlated in the MMR II group. The comparison group showed no such correlation.
 
Interestingly within the MMR II group, those who have been functional immune of asymptomatic had the highs levels of mumps titers (134 to 300 AU/ml). As mumps titers levels reduced, COVID-19 symptoms became more pronounced. Levels of less than 134 AU/ml were found in those with mild symptoms, and those with moderate symptoms all had titers belt 75 AU/ml.
 
The study team highlights how the study's findings may be instrumental in developing future strategies to protect people from severe cases of COVID-19, “The study findings add to other associations demonstrating that the MMR vaccine may be protective against COVID-19. It also may explain why children have a much lower COVID-19 case rate than adults, as well as a much lower death rate. The majority of children get their first MMR vaccination around 12 to 15 months of age and a second one from 4 to 6 years of age."
 
This is the first immunological study to investigate the relationship between the MMR II vaccine and symptom severity of COVID-19, the scientists were able to uncover evidence to support the hypothesis that MMR II vaccinations may protect people from severe symptoms of COVID-19.
 
Importantly the significant inverse correlation found between mumps titers and COVID-19 symptom severity requires further research.
 
However, given the MMR II vaccine's established safety, the results point to a possible accessible, cost-effective, and safe method for protecting people from severe symptoms of COVID-19 and even hospitalization.
 
Several clinical trials are now ongoing with BCG vaccination of SARS‐CoV‐2 exposed health‐care workers in an attempt to reduce the severity of an eventual infection. However, one of the effects described in the above experiments with BCG‐trained‐immunity was a rise in IL‐6, which made the study team reluctant to use this method due to immune over‐activation described in severe COVID‐19 cases linked to high IL‐6 levels.
 
Apart from probably having a better safety profile, there are three reasons that made us think we could apply the concept of trained immunity administering the MMR vaccine.
 
-Another previous described trained immunity in newborn infants of HBV‐infected mothers, showing the effect can also be obtained when training the innate immune system with a virus. https://pubmed.ncbi.nlm.nih.gov/25807344/
 
-All‐cause mortality rates dropped 26%‐49% after introducing massive measles vaccination.
https://pubmed.ncbi.nlm.nih.gov/27737834/
 
-COVID‐19 case fatality rates among young children have been 1/1000 from those in adults, even in countries with no standard BCG vaccination. However, globally young children receive between 10 to 15  viral vaccines before the age of six.
 
Also it is possible that MMR vaccines may provide a route to reducing preventing infection, reducing the spread of the virus, and reducing symptom severity.
 
Further studies are required before a firm conclusion on the role of MMR in fighting COVID-19 can be established.
 
For more on COVID-19 Protection, keep on logging to Thailand Medical News.